The Novo Nordisk Foundation has allocated up to DKK 5.5 billion (EUR 736 million) to BioInnovation Institute (BII), a leading institute for life science and deep tech innovation in Copenhagen. The funding will enable BII to expand its activities into new strategic areas and geographies, and support even more entrepreneurs and start-up-companies, thereby strengthening innovation […]
How can companies with promising science secure the capital they need to develop drugs What does pharma need to fill their pipelines as they look to negotiate looming patent cliffs London, UK, 7 October 2025: Optimum Strategic Communications (Optimum), the specialist life sciences communications consultancy, will be hosting its 17th Annual Healthcare Investor Conference on Thursday 9 October […]
New funding follows US expansion and will accelerate Phasecraft’s R&D to develop practical applications in collaboration with end users Phasecraft is developing algorithms that bridge the gap between today’s noisy quantum computers and tomorrow’s world-changing applications Copenhagen, Denmark, 2 September 2025 – Novo Holdings, a leading life science investor, today announced it has co-led the $34 […]
The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from all over the globe, including Denmark, Sweden, The Netherlands, Belgium, Germany, Australia, and the USA. Read more…
Copenhagen, Denmark: The Novo Nordisk Foundation today announced the latest edition of its annual Challenge Programme, where for the first time it is inviting researchers from outside Denmark, in the European Schengen area, Ireland and the UK, to lead collaborations applying for grants to study four major themes. As part of its ongoing internationalisation, the […]
